HYL Stock Overview
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hyloris Pharmaceuticals SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €11.95 |
| 52 Week High | €14.10 |
| 52 Week Low | €10.60 |
| Beta | 0.58 |
| 1 Month Change | 5.75% |
| 3 Month Change | -7.00% |
| 1 Year Change | -7.00% |
| 3 Year Change | -10.15% |
| 5 Year Change | n/a |
| Change since IPO | 15.01% |
Recent News & Updates
Shareholder Returns
| HYL | BE Pharmaceuticals | BE Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 2.4% |
| 1Y | -7.0% | 7.5% | -2.8% |
Return vs Industry: HYL underperformed the Belgian Pharmaceuticals industry which returned 5.7% over the past year.
Return vs Market: HYL underperformed the Belgian Market which returned -3.3% over the past year.
Price Volatility
| HYL volatility | |
|---|---|
| HYL Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in BE Market | 7.7% |
| 10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: HYL has not had significant price volatility in the past 3 months.
Volatility Over Time: HYL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 42 | Stijn Van Rompay | hyloris.com |
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. The company provides Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative non-opioid pain management; Tranexamic acid RTU, an antifibrinolytic drug for the formation of blood clots; Miconazole/Domiphen Bromide, a topical synergistic combination treatment for Recurrent Vulvovaginal Candidiasis; AlenuraTM, a first-line drug treatment for acute pain in interstitial cystitis/bladder pain syndrome; and Plecoid Agent IV for the treatment of acute myeloid leukemia and small cell lung cancer.
Hyloris Pharmaceuticals SA Fundamentals Summary
| HYL fundamental statistics | |
|---|---|
| Market cap | €334.60m |
| Earnings (TTM) | -€15.76m |
| Revenue (TTM) | €2.81m |
118.9x
P/S Ratio-21.2x
P/E RatioIs HYL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HYL income statement (TTM) | |
|---|---|
| Revenue | €2.81m |
| Cost of Revenue | €93.00k |
| Gross Profit | €2.72m |
| Other Expenses | €18.48m |
| Earnings | -€15.76m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 96.70% |
| Net Profit Margin | -560.13% |
| Debt/Equity Ratio | 0% |
How did HYL perform over the long term?
See historical performance and comparison